Dupix­ent wins FDA OK for asth­ma; Seres poach­es new CMO from As­traZeneca

Sanofi and Re­gen­eron won FDA ap­proval to mar­ket Dupix­ent for asth­ma. “Dupix­ent is now ap­proved in the U.S. for two im­por­tant groups of un­con­trolled asth­ma pa­tients – those who are mod­er­ate-to-se­vere with an eosinophilic phe­no­type or those with oral cor­ti­cos­teroid-de­pen­dent asth­ma,” said George Yan­copou­los, pres­i­dent and CSO of Re­gen­eron.

As­traZeneca vet Kevin Hor­gan is jump­ing over to Cam­bridge, MA-based Seres as its new CMO. “Kevin is an ac­com­plished drug de­vel­op­er with ex­ten­sive ex­pe­ri­ence suc­cess­ful­ly lead­ing nu­mer­ous mid- and late-stage clin­i­cal pro­grams to ap­proval. Seres’ R&D ef­forts are in­creas­ing­ly fo­cused on ear­ly and lat­er stage im­muno­log­i­cal in­di­ca­tions, and Kevin’s deep clin­i­cal back­ground in these ar­eas makes him very well suit­ed to lead our clin­i­cal de­vel­op­ment stud­ies,” said Seres CEO Roger Pomer­antz.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.